Intraoperative massive bleeding. Hemorrhagic condition, unspecified
Conditions
Interventions
Intervention 1: Infusion of 1 g fibrinogen powder(CSL Behring,USA) in 20 milliliter saline normal intravenously before anesthesia in case group. Intervention 2: Infusion of 20 milliliter saline normal
Prevention
Placebo
Infusion of 1 g fibrinogen powder(CSL Behring,USA) in 20 milliliter saline normal intravenously before anesthesia in case group
Infusion of 20 milliliter saline normal before anesthesia in control group
Sponsors
Iran University of Medical Sciences, Vice chancellor for research
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients candidate for elective posterior spine fusion surgery, preoperative serum fibrinogen level between 2-4 g/l, ASA I,II , age 18-60y, BMI less than 30 kg/m2, duration of surgery between 1-4 h, Exclusion criteria: history of previous PSF, pulmonary, cardiac, hepatic, renal or coagulation disorders, hypertension, using beta blocker, calcium blocker, digoxine, TCAs, anticoagulant and clonidin by patient, alcohol or drug abuse, existing tumor in the site of surgery, surgery in more than 3 levels
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of bleeding. Timepoint: during surgery and in recovery room. Method of measurement: Watching scaled bottle of suction in milliliter.;Number of infused Blood bags. Timepoint: At the end of surgery. Method of measurement: Counting the number of infused blood bags.;Serum fibrinogen. Timepoint: just before and the day after surgery. Method of measurement: Special laboratory kit for measuring fibrinogen.;Hemoglobin. Timepoint: The day before and 4 hours after surgery. Method of measurement: Measurement of hemoglobin by laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Pournajafian
Firoozgar Hospital
Outcome results
None listed